📊 BIIB Key Takeaways
Is Biogen Inc.. (BIIB) a Good Investment?
Biogen demonstrates solid operational profitability with 15.7% operating margin and strong free cash flow generation ($2.1B), supported by a healthy balance sheet with 2.68x current ratio and manageable 0.34x debt-to-equity. However, revenue growth is anemic at 2.2% YoY with flat net income growth and diluted EPS declining 21.4%, indicating challenges in product pipeline execution or market competition that offset operational efficiency.
Biogen shows solid fundamental stability with strong free cash flow generation, healthy liquidity, and manageable leverage, which supports financial resilience. However, growth quality looks mixed: revenue growth is modest, net income is flat, diluted EPS declined sharply, and the reported gross margin above 100% suggests either unusual accounting dynamics or data-quality distortion that reduces clarity around underlying profitability.
Why Buy Biogen Inc.. Stock? BIIB Key Strengths
- Strong free cash flow generation at $2.1B with 20.7% FCF margin provides capital flexibility
- Solid liquidity position with 2.68x current ratio and 2.03x quick ratio supporting operational stability
- Healthy interest coverage of 5.8x and conservative 0.34x debt-to-equity ratio indicate low financial distress risk
- Consistent gross margin at 117.7% suggests pricing power and cost management despite sector pressures
- Strong free cash flow generation with a 20.7% FCF margin and low capital intensity
- Healthy balance sheet with 2.68x current ratio, 2.03x quick ratio, and moderate 0.34x debt-to-equity
- Positive top-line growth and continued profitability with $1.29B net income and $2.20B operating cash flow
BIIB Stock Risks: Biogen Inc.. Investment Risks
- Stagnant revenue growth at 2.2% YoY with zero net income growth signals potential product portfolio challenges or market saturation
- Significant EPS decline of 21.4% year-over-year despite flat net income suggests share dilution or unfavorable capital allocation
- Low ROE of 7.1% and ROA of 4.4% indicate modest returns on capital despite substantial asset base of $29.4B
- Elevated gross margin at 117.7% appears anomalous and may indicate accounting irregularities or non-operating gains requiring clarification
- Growth is modest, with revenue up only 2.2% year over year and net income essentially flat
- Diluted EPS fell 21.4% year over year, signaling weaker per-share earnings quality
- Reported gross margin of 117.7% is anomalous and raises concern about metric reliability or nonrecurring accounting effects
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution rates
- Operating margin sustainability and R&D spending efficiency
- Free cash flow consistency and capital allocation strategy
- Return on equity improvement and share dilution trends
- Operating margin and net income conversion from revenue growth
- Diluted EPS trend relative to net income and free cash flow
Biogen Inc.. (BIIB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 20.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.68x current ratio provides a solid financial cushion.
BIIB Profit Margin, ROE & Profitability Analysis
BIIB vs Healthcare Sector: How Biogen Inc.. Compares
How Biogen Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biogen Inc.. Stock Overvalued? BIIB Valuation Analysis 2026
Based on fundamental analysis, Biogen Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biogen Inc.. Balance Sheet: BIIB Debt, Cash & Liquidity
BIIB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biogen Inc..'s revenue has declined by 31% over the 5-year period, indicating business contraction. The most recent EPS of $7.97 reflects profitable operations.
BIIB Revenue Growth, EPS Growth & YoY Performance
BIIB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5B | $388.5M | $2.66 |
| Q2 2025 | $2.5B | $583.6M | $4.00 |
| Q1 2025 | $2.3B | $240.5M | $1.64 |
| Q3 2024 | $2.5B | -$68.1M | $-0.47 |
| Q2 2024 | $2.5B | $583.6M | $4.00 |
| Q1 2024 | $2.3B | $387.9M | $2.67 |
| Q3 2023 | $2.5B | -$68.1M | $-0.47 |
| Q2 2023 | $2.5B | $591.6M | $4.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biogen Inc.. Dividends, Buybacks & Capital Allocation
BIIB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biogen Inc.. (CIK: 0000875045)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIIB
What is the AI rating for BIIB?
Biogen Inc.. (BIIB) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIIB's key strengths?
Claude: Strong free cash flow generation at $2.1B with 20.7% FCF margin provides capital flexibility. Solid liquidity position with 2.68x current ratio and 2.03x quick ratio supporting operational stability. ChatGPT: Strong free cash flow generation with a 20.7% FCF margin and low capital intensity. Healthy balance sheet with 2.68x current ratio, 2.03x quick ratio, and moderate 0.34x debt-to-equity.
What are the risks of investing in BIIB?
Claude: Stagnant revenue growth at 2.2% YoY with zero net income growth signals potential product portfolio challenges or market saturation. Significant EPS decline of 21.4% year-over-year despite flat net income suggests share dilution or unfavorable capital allocation. ChatGPT: Growth is modest, with revenue up only 2.2% year over year and net income essentially flat. Diluted EPS fell 21.4% year over year, signaling weaker per-share earnings quality.
What is BIIB's revenue and growth?
Biogen Inc.. reported revenue of $9.9B.
Does BIIB pay dividends?
Biogen Inc.. does not currently pay dividends.
Where can I find BIIB SEC filings?
Official SEC filings for Biogen Inc.. (CIK: 0000875045) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIIB's EPS?
Biogen Inc.. has a diluted EPS of $8.79.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BIIB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biogen Inc.. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BIIB stock overvalued or undervalued?
Valuation metrics for BIIB: ROE of 7.1% (sector avg: 15%), net margin of 13.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BIIB stock in 2026?
Our dual AI analysis gives Biogen Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is BIIB's free cash flow?
Biogen Inc..'s operating cash flow is $2.2B, with capital expenditures of $153.8M. FCF margin is 20.7%.
How does BIIB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 13.1% (avg: 12%), ROE 7.1% (avg: 15%), current ratio 2.68 (avg: 2).